Meta-analysis of regimen SOX versus XELOX in treatment of Chinese patients with advanced gastric carcinoma
- VernacularTitle:奥沙利铂联合替吉奥（SOX）与奥沙利铂联合卡培他滨（XELOX）治疗中国进展期胃癌患者的Meta分析
- Author:
Yuanjun LI
;
Juan XING
;
Hanchang WU
;
Xu WEI
;
Hongmei ZHANG
- Publication Type:Journal Article
- Keywords:
advanced gastric carcinoma;
SOX;
XELOX;
Meta-analysis
- From:
Chinese Journal of Biochemical Pharmaceutics
2015;37(5):56-60
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare clinical outcome and adverse reactions between the regimens SOX and XELOX for chemotherapy of advanced gastric carcinoma in Chinese population.Methods The original articles on randomized controlled trials ( RCTs) comparing the chemotherapy of SOX and XELOX in Chinese patients with advanced gastric carcinoma were recruited from the PUBMED, WANFANG, VIP and CNKI databases.The quality of the selected trials were assessed by JADAD method.Meta-analysis about the efficacy and safety of the two chemotherapy methods was performed by Rev Man 5.2.0 software ( Cochrane-information Management System) .Results Eight RCT studies were recruited in our work, including 293 patients in the SOX treatment group and 310 in the XELOX treatment group.The analysis results showed that there was no significant difference in the effect of the two chemotherapy methods (OR=1.19, 95%CI:0.86-1.64,P=0.29), and referred to the safety evaluation, the stomatitis (OR=2.29, 95%CI:1.74-4.89, P<0.0001) incidence in SOX treatment group was higher than XELOX treatment group, and in total, there was no significant difference in adverse reaction incidence of the two chemotherapy methods(OR =0.88, 95%CI: 0.66-1.19, P =0.41).Conclusion In the chemotherapy of advanced gastric carcinoma in Chinese population, there is no significant difference in clinical response rate between SOX and XELOX, and the stomatitis incidence of SOX is significantly higher than that of XELOX.
